A prospective study was undertaken to assess the therapeutic role of the antiobiotic ciprofloxacin as an adjunct to corticosteroids in acute severe ulcerative colitis.
The researchers reported their findings in the September issue of the Scandinavian Journal of Gastroenterology.
The randomized, double-blind trial involved 55 consecutive patients with severe ulcerative colitis.
|Corticosteroid treatment for UC not augmented by ciprofloxacin.|
|Scandinavian Journal of Gastroenterology|
Ciprofloxacin (400 mg b.i.d, n = 29) or placebo (n = 27) were administered. All patients additionally received parenteral nutrition, intravenous hydrocortisone (100 mg q.i.d.) and hydrocortisone enemas (100 mg b.i.d.).
Assessment was after 10 days of continuous treatment, or at any time a severe complication occurred.
23 of the patients (79%) treated with ciprofloxacin and 20 (77%) treated with placebo showed substantial improvement, and were switched to oral steroids.
6 patients in each group did not improve or developed complications.
9 of these 12 patients underwent emergency colectomy.
3 patients consented to receive intravenous cyclosporin, but did not achieve remission of their colitis, and they underwent elective colectomy.
There were no perioperative or late deaths.
Researcher G. J. Mantzaris of the Evangelismos Hospital, Athens, Greece, concluded on behalf of the group, "A short course of intravenous ciprofloxacin does not seem to augment the effect of corticosteroids for patients with acute, severe ulcerative colitis."